Efficacy News and Research

RSS

Implementing population level changes could avoid up to 50% of deaths from CVD

Up to 50% of deaths from cardiovascular disease in Europe could be avoided by implementing population level changes such as taxation and regulation of advertising. Population level prevention will produce greater impacts on CVD than individualised approaches, according to the European Association for Cardiovascular Prevention & Rehabilitation (EACPR) of the European Society of Cardiology (ESC).

24 Jul 2012

Debiopharm initiates Debio 8206 Phase III study on advanced prostate cancer

Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs and companion diagnostics, today announced the treatment of its first patient in a multicentre, open, non-comparative Phase III study to investigate the efficacy, safety, and pharmacokinetics of two subcutaneous (SC) injections of Debio 8206 (triptorelin pamoate 22.5 mg 6-month formulation) in patients with advanced prostate cancer.

24 Jul 2012

Forest Pharmaceuticals receives FDA approval for Tudorza Pressair to treat COPD

The U.S. Food and Drug Administration today approved Tudorza Pressair (aclidinium bromide) for the long-term maintenance treatment of bronchospasm (narrowing of the airways in the lung) associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

24 Jul 2012

Once-daily Gralise significantly reduces pain intensity in PHN patients

Depomed, Inc. today announced that a report of Phase 3 data published online this month, ahead of the print edition, in the Clinical Journal of Pain showed that once-daily Gralise (gabapentin) tablets (1,800 mg) formulation significantly reduces intensity of pain in patients with postherpetic neuralgia (PHN).

23 Jul 2012

Top-line results in Pfizer's Lyrica long term safety study for Generalized Anxiety Disorder

Pfizer Inc. announced today that top-line results for Lyrica (pregabalin) capsules Study A0081147 - Long Term Safety and Efficacy of Pregabalin in Subjects with Generalized Anxiety Disorder (GAD) - demonstrate that drug discontinuation symptoms were low after tapering Lyrica treatment following three months and six months in GAD patients.

23 Jul 2012

Positive results from BrainStorm's interim NurOwn stem cell therapy clinical trial for ALS

BrainStorm Cell Therapeutics announced today that it has completed the planned interim safety review of its Phase I/II ALS (Amyotrophic Lateral Sclerosis) clinical trial, indicating that autologous transplantation of the Company's cell therapy was well-tolerated, appears to be safe for use, and did not present any undue risks to the study participants.

23 Jul 2012

Herbal therapy no alternative in HCV infection

The commonly used herbal remedy, silymarin, offers no benefit to patients with treatment-resistant hepatitis C virus infection, a study shows.

23 Jul 2012

Pneumococcal revaccination needed in kidney transplant patients

Kidney transplant patients vaccinated against Streptococcus pneumoniae appear to be protected against pneumococcal infection for at least 15 months, research shows.

23 Jul 2012

Linagliptin safe and effective for long-term management of type 2 diabetes

An extended trial of a drug for people with type 2 diabetes has confirmed that the oral DPP-4 inhibitor linagliptin is a safe and effective means of lowering glucose levels for up to 102 weeks, either on its own or in combination with other selected oral anti-diabetic medication.

23 Jul 2012

Bayer, Onyx and Astellas announce results from Tarceva plus Nexavar Phase 3 trial on HCC

Bayer HealthCare Pharmaceuticals, Onyx Pharmaceuticals, Inc., and Astellas Pharma Inc. today announced that a Phase 3 trial evaluating the efficacy and safety of the addition of Tarceva (erlotinib) tablets to Nexavar (sorafenib) tablets did not improve overall survival for patients with unresectable hepatocellular carcinoma (HCC) vs. Nexavar alone.

23 Jul 2012

International Congress on Natural Products Research to be held in New York City

The urgent need to evaluate nature's repository of chemicals in plants, microbes, and marine organisms for their potential value in health care will be a major theme of a five-day scientific conference in New York that is expected to draw some 1,200 natural products researchers from around the world.

21 Jul 2012

New CHAIT initiative on development of novel immunological therapeutic interventions

The CHAIT initiative is a public-private partnership focusing on the development of novel immunological therapeutic interventions to achieve a 'functional HIV cure' with the ultimate goal of HIV eradication.

21 Jul 2012

FDA grants accelerated approval for Kyprolis to treat multiple myeloma

Ligand Pharmaceuticals Incorporated today announced that its licensee, Onyx Pharmaceuticals, received accelerated approval from the U.S. Food and Drug Administration (FDA) for Kyprolis (carfilzomib) for Injection, a proteasome inhibitor indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of completion of the last therapy.

21 Jul 2012

Study explores role of L. reuteri against foodborne infection

While many bacteria exist as aggressive pathogens, causing diseases ranging from tuberculosis and cholera, to plague, diphtheria and toxic shock syndrome, others play a less malevolent role and some are critical for human health.

21 Jul 2012

FDA grants accelerated approval to Onyx's Kyprolis for treatment of multiple myeloma

Onyx Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Kyprolis (carfilzomib) for Injection, a proteasome inhibitor, indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of completion of the last therapy.

21 Jul 2012

Regeneron, Sanofi initiate enrollment in SAR236553/REGN727 Phase 3 program

Sanofi and Regeneron Pharmaceuticals, Inc. announced today that several trials within ODYSSEY, the Phase 3 clinical program of SAR236553/REGN727, have initiated patient enrollment.

21 Jul 2012

Silymarin does not offer significant improvements for patients with HCV

Silymarin, an extract of milk thistle commonly used to treat chronic liver disease by millions of people around the World, does not offer significant improvements for patients, according to a new study conducted by a nationwide group of researchers including faculty at the Perelman School of Medicine at the University of Pennsylvania.

20 Jul 2012

Studies report on therapeutic efficacy of stem cell transplantation in animal models of ALS, SCI

Two studies published in a recent issue of Cell Medicine report on the therapeutic efficacy of stem cell transplantation in animal models of amyotrophic lateral sclerosis (ALS) and spinal cord injury (SCI).

20 Jul 2012

CPAP effectively reduces symptoms and improves QOL in sleepy patients with milder OSA

Continuous positive airway pressure (CPAP), well established as an effective treatment for severe obstructive sleep apnea (OSA), is also effective in patients with mild and moderately severe OSA and daytime sleepiness, according to a new study.

20 Jul 2012

FDA clears pSivida's IND for injectable sustained-release micro-insert to treat posterior uveitis

pSivida Corp., a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to treat posterior uveitis with pSivida's injectable sustained-release micro-insert.

20 Jul 2012

Efficacy News and Research

Implementing population level changes could avoid up to 50% of deaths from CVD

Debiopharm initiates Debio 8206 Phase III study on advanced prostate cancer

Forest Pharmaceuticals receives FDA approval for Tudorza Pressair to treat COPD

Once-daily Gralise significantly reduces pain intensity in PHN patients

Top-line results in Pfizer's Lyrica long term safety study for Generalized Anxiety Disorder

Positive results from BrainStorm's interim NurOwn stem cell therapy clinical trial for ALS

Herbal therapy no alternative in HCV infection

Pneumococcal revaccination needed in kidney transplant patients

Linagliptin safe and effective for long-term management of type 2 diabetes

Bayer, Onyx and Astellas announce results from Tarceva plus Nexavar Phase 3 trial on HCC

International Congress on Natural Products Research to be held in New York City

New CHAIT initiative on development of novel immunological therapeutic interventions

FDA grants accelerated approval for Kyprolis to treat multiple myeloma

Study explores role of L. reuteri against foodborne infection

FDA grants accelerated approval to Onyx's Kyprolis for treatment of multiple myeloma

Regeneron, Sanofi initiate enrollment in SAR236553/REGN727 Phase 3 program

Silymarin does not offer significant improvements for patients with HCV

Studies report on therapeutic efficacy of stem cell transplantation in animal models of ALS, SCI

CPAP effectively reduces symptoms and improves QOL in sleepy patients with milder OSA

FDA clears pSivida's IND for injectable sustained-release micro-insert to treat posterior uveitis

Industry Focus eBook - Cell biology (5th edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News